Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Overview
Date Founded

2012

Headquarters

Marina One East Tower,7 Straits View,Suite 12-00,Singapore, Central Singapore 018936

Type of Company

Public

Employees (Worldwide)

250

Industries

Power & Utilities
Medical Products & Equipment
Biotechnology

Company Description

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Contact Data
Trying to get in touch with decision makers at Wave Life Sciences Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Chief Financial Officer & Chief Accounting Officer

General Counsel

Chief Medical Officer

Chief Human Resources Officer

Senior Vice President, Corporate Development & Head of Emerging Areas

Senior Vice President-Operations & Business Analytics

Senior Vice President, Drug Discovery

Senior Vice President, Technical Operations

Vice President, Public Affairs

Board of Directors

Director-Scientific Counselors at Memorial Sloan-Kettering Cancer Center

Professional at Wave Life Sciences Ltd.

Founder at RA Capital Management LLC

Chief Financial Officer & Principal Accounting Officer at Adaptimmune Therapeutics PLC

President, Chief Executive Officer & Director at Wave Life Sciences Ltd.

Chief Operating Officer, Representative Director & Vice President at Shin Nippon Biomedical Laboratories, Ltd.

Managing Director at Miura & Associates Management Consultants Pte Ltd.

Paths to Wave Life Sciences Ltd.
Potential Connections via
Relationship Science
You
Wave Life Sciences Ltd.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Tavistock Life Sciences invests in a portfolio of public companies and private equity crossover opportunities. Investments tend to focus on focus on biotechnology drug development companies across multiple therapeutic indications.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Recent Transactions
Details Hidden

Wave Life Sciences Ltd. issued USD Ordinary Shares

Details Hidden

Wave Life Sciences Ltd. issued USD Common Stock

Details Hidden

Wave Life Sciences Ltd. issued USD Ordinary Shares

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Escrow Agent

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Underwriter

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Professional

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Managing Director

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Underwriter

Advised onWave Life Sciences Ltd. issued USD Ordinary Shares

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2018
Market Capitalization
$875M
Total Enterprise Value
$1.05B
Earnings Per Share
$-5.06
Net Profit
$-147M
EBITDA
$-154M
EBITDAMargin
-1,068%
Total Debt
$0
Total Equity
$81.2M
Revenue
$14.4M
Enterprise Value Sales
72.91x
TEVNet Income
-7.17x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
353.18%
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Clough Capital Partners employs a fundamental research-driven investment process that seeks to earn superior long-term rates of return for their clients relative to broad equity market indices, such as the S&P 500 Index and the Morgan Stanley World Index. The firm invests its clients' assets primarily in equity and equity-related securities in both US and non-US markets. Clough Capital may also invest clients' assets in fixed income securities and other financial instruments including equity and index options, futures, currencies, and commodities. Investments in non-US markets are made primarily through securities that trade on non-US exchanges and through securities that do trade on US exchanges such as ETFs, GDRs and ADRs. Along with capital appreciation, capital preservation is a primary objective. Clough Capital may use hedging strategies to attempt to provide a degree of protection against market declines, such as shorting individual stocks and using index options and futures. In addition, short positions and put options may also be used to implement independent investment strategies. Clough Capital generally expects to keep accounts in a net long position and will also utilize leverage when deemed appropriate.

Suppliers
Max Planck Society Publishing | Munich, BV

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of German research institutes publicly funded by the federal and the 16 state governments of Germany. It is named in honor of its former president, theoretical physicist Max Planck. The 82 research institutes of the Max Planck Society (as 2013) conduct basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 17,000 permanent employees, including 5,470 scientists, plus around 4,500 non-tenured scientists and guests. The Max Planck Society has a world-leading reputation as a science & technology research organization, with 32 Nobel Prizes awarded to their scientists, and are generally regarded as the foremost basic research organization in Europe and the world.

The University of Tokyo was established in 1877 as the first national university in Japan. As a leading research university, UTokyo offers courses in essentially all academic disciplines at both undergraduate and graduate levels and conducts research across the full spectrum of academic activity. The University aims to provide its students with a rich and varied academic environment that ensures opportunities for both intellectual development and the acquisition of professional knowledge and skills. To learn more about the University of Tokyo, please visit the pages below.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

SAGE Therapeutics, Inc. Pharmaceuticals - CAMBRIDGE, MA

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Wave Life Sciences Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Wave Life Sciences Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Wave Life Sciences Ltd..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/wave-life-sciences-ltd-155003252
  • https://relationshipscience.com/organization/wave-life-sciences-ltd-155003252